Beam Therapeutics BEAM 深 滬
已收盤 12-24 16:00:00 美东时间
28.14
+0.370
+1.33%
華盛通- 最 高28.29
- 今 開27.92
- 成交量 43.03万股
- 最 低 27.50
- 昨 收 27.77
- 總市值 28.42亿
- 52周最高 35.25
- 市盈率 靜 --
- 換手率 0.43%
- 52周最低 13.525
- 委 比 -85.06%
- 總股本 1.01亿
- 歷史最高 138.522
- 量 比 0.26
- 振 幅 2.84%
- 歷史最低 13.00
- 每 手 1
- 風險率 4.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多2026美股生物科技板块怎么投资？杰富瑞：关注6大首选、7大潜力和5大并购目标
杰富瑞近日发布了关于 2026 年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
12-25 15:40
2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标
杰富瑞近日发布了关于2026年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。该行指出，2026年生物科技领域将迎来多项关键临...
12-24 17:33
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company focused on precision genetic medicines via base editing, announced that CEO John Evans will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, in San Francisco at 5:15 p.m. PT. The live webcast will be available on the company's investor website, www.beamtx.com, and archived for 60 days. Beam is dedicated to advancing base editing technology for potentia...
12-18 21:01
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 9, 2025 /PRNewswire/ -- Equity Insider News Commentary – Traditional pharmaceutical strategies are giving ground as breakthrou...
12-10 00:57
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics announced updated data from its BEACON trial for risto-cel, showing promising results in 31 patients with severe sickle cell disease (SCD). The therapy achieved mean hemoglobin F (HbF) induction of over 60%, reduced hemoglobin S (HbS) to below 40%, and resolved anemia durably for up to 20 months. Patients required a median of one cell collection cycle and experienced rapid neutrophil and platelet engraftment. The safety profile ...
12-06 13:00
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Cathie Wood Bets Big On This Peter Thiel-Backed Coinbase Rival As Bitcoin Crashes Below $91,000
On Monday, Cathie Wood-led Ark Invest executed significant trades involving Bullish (NYSE:BLSH), Reddit Inc.
11-18 10:42
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
<p>Beam Therapeutics Inc. announced that its management will participate in a fireside chat at the 2025 Jefferies London Healthcare Conference on November 19, 2025. The live webcast will be available on the company's website and archived for 60 days. Beam Therapeutics is a biotechnology company focused on precision genetic medicines, utilizing base editing technology to enable precise, predictable, and efficient single base changes in genomic seq...
11-12 12:00
Beam Therapeutics Q3 EPS $(1.10) Misses $(1.05) Estimate, Sales $9.698M Miss $12.368M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(1.05) by 5.16 percent. This is a 5.98 percent increase over losses of $(1.17) per share from
11-04 20:09
Beam Therapeutics To Present Updated Safety, Efficacy Data From BEACON Phase 1/2 Clinical Study Of BEAM-101 In Sickle Cell Disease At American Society Of Hematology
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy data from the BEACON
11-03 22:16
